Share Price and Basic Stock Data
Last Updated: November 3, 2025, 8:02 pm
| PEG Ratio | 41.31 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Zydus Wellness Ltd operates within the food processing sector, focusing on bakery, dairy, and fruit products. As of the latest reporting, the company’s share price stood at ₹494, with a market capitalization of ₹15,714 Cr. The revenue trajectory has shown a consistent upward trend, recording sales of ₹2,255 Cr in FY 2023, which rose to ₹2,328 Cr in FY 2024, and further increased to ₹2,709 Cr for FY 2025. This growth reflects a robust demand for its product offerings, aligning with the general trend in the food processing industry, which has been buoyant due to rising consumer preferences for packaged foods. The quarterly sales data also illustrate this growth, with sales peaking at ₹913 Cr in Mar 2025. Such performance indicates Zydus Wellness’s ability to adapt to market dynamics and consumer demands effectively.
Profitability and Efficiency Metrics
The company’s profitability metrics reveal a mixed performance. Zydus Wellness reported a net profit of ₹347 Cr for FY 2025, a notable increase from ₹310 Cr in FY 2023. However, the operating profit margin (OPM) has shown variability, decreasing from 15% in FY 2023 to 14% in FY 2025. The return on equity (ROE) stood at 6.02%, while the return on capital employed (ROCE) was recorded at 6.16%. The interest coverage ratio, at 32.77x, indicates robust capacity to meet interest obligations, reflecting financial prudence. While these figures are generally favorable, the declining OPM raises concerns about cost management and pricing power in a competitive market. The cash conversion cycle (CCC) of 75 days suggests that the company efficiently manages its working capital, although the increasing inventory days may warrant closer monitoring.
Balance Sheet Strength and Financial Ratios
Zydus Wellness maintains a healthy balance sheet, with total assets amounting to ₹6,442 Cr and reserves reported at ₹5,608 Cr. The company has minimal borrowings, standing at ₹188 Cr, which contributes to a low total debt-to-equity ratio of 0.03x, indicating a conservative capital structure. The price-to-book value (P/BV) ratio is 1.87x, suggesting the stock is trading at a premium to its book value, which may reflect investor confidence in future growth prospects. The current ratio of 1.48x indicates adequate liquidity to meet short-term liabilities. However, the declining ROCE percentage, which has hovered around 6%, suggests that while the company is profitable, it may not be utilizing its capital to its fullest potential. This could be an area for improvement to enhance shareholder value.
Shareholding Pattern and Investor Confidence
The shareholding structure of Zydus Wellness indicates a strong promoter presence, with promoters holding 69.64% of the company as of Mar 2025. This level of control is beneficial for long-term strategic direction. Foreign institutional investors (FIIs) hold 3.43%, while domestic institutional investors (DIIs) account for 18.76%. The public shareholding stands at 8.18%, reflecting a healthy distribution that supports liquidity. The number of shareholders has increased to 77,188, which indicates growing interest and confidence among retail investors. However, the decline in DII holdings from 23.35% in Dec 2022 to 18.76% in Mar 2025 may signal caution among institutional investors regarding future performance, potentially impacting stock liquidity and investor sentiment.
Outlook, Risks, and Final Insight
Zydus Wellness faces a promising outlook driven by increasing consumer demand in the packaged food sector. However, the company must navigate several risks, including fluctuating raw material prices that could pressure margins and an increasingly competitive landscape that may affect market share. Additionally, the variability in its operating profit margin necessitates a focus on cost management and operational efficiency. On the upside, if the company successfully leverages its strong balance sheet and enhances operational efficiency, it could improve profitability and shareholder returns. Conversely, failure to address these challenges could lead to stagnation. Overall, Zydus Wellness stands at a crossroads where strategic focus and execution will determine its ability to capitalize on growth opportunities in the food processing industry.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Zydus Wellness Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Mishtann Foods Ltd | 564 Cr. | 5.23 | 15.9/4.28 | 1.63 | 8.92 | 0.00 % | 42.2 % | 44.1 % | 1.00 |
| Mrs Bectors Food Specialities Ltd | 8,149 Cr. | 1,327 | 1,977/1,201 | 58.8 | 190 | 0.45 % | 18.1 % | 15.6 % | 10.0 |
| Nakoda Group of Industries Ltd | 52.3 Cr. | 29.8 | 48.0/25.2 | 15.7 | 0.00 % | 8.11 % | 15.4 % | 10.0 | |
| HMA Agro Industries Ltd | 1,574 Cr. | 31.5 | 49.5/27.5 | 18.2 | 15.8 | 0.95 % | 11.8 % | 11.5 % | 1.00 |
| Himalaya Food International Ltd | 95.1 Cr. | 11.2 | 21.1/9.29 | 18.7 | 16.4 | 0.00 % | 2.29 % | 2.79 % | 10.0 |
| Industry Average | 21,480.71 Cr | 765.32 | 120.80 | 104.40 | 0.23% | 16.32% | 17.50% | 6.03 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 696 | 429 | 416 | 713 | 702 | 440 | 403 | 783 | 841 | 493 | 462 | 913 | 861 |
| Expenses | 548 | 413 | 388 | 568 | 586 | 423 | 390 | 620 | 686 | 473 | 447 | 723 | 705 |
| Operating Profit | 148 | 16 | 28 | 145 | 116 | 17 | 13 | 162 | 155 | 20 | 15 | 190 | 156 |
| OPM % | 21% | 4% | 7% | 20% | 17% | 4% | 3% | 21% | 18% | 4% | 3% | 21% | 18% |
| Other Income | -1 | 1 | 1 | -6 | -12 | 4 | 3 | 4 | 5 | 10 | 4 | 1 | 3 |
| Interest | 4 | 3 | 4 | 5 | 5 | 6 | 6 | 6 | 4 | 1 | 3 | 4 | 2 |
| Depreciation | 6 | 6 | 6 | 7 | 6 | 6 | 6 | 6 | 5 | 5 | 5 | 13 | 11 |
| Profit before tax | 137 | 8 | 19 | 126 | 93 | 9 | 4 | 154 | 152 | 24 | 10 | 173 | 145 |
| Tax % | 0% | -4% | -1% | -15% | -18% | 31% | 92% | 3% | 3% | 12% | 37% | 1% | 12% |
| Net Profit | 137 | 8 | 20 | 145 | 110 | 6 | 0 | 150 | 148 | 21 | 6 | 172 | 128 |
| EPS in Rs | 21.53 | 1.34 | 3.08 | 22.83 | 17.35 | 0.93 | 0.05 | 23.62 | 23.21 | 3.28 | 1.01 | 27.01 | 20.10 |
Last Updated: August 2, 2025, 1:05 am
Below is a detailed analysis of the quarterly data for Zydus Wellness Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 861.00 Cr.. The value appears to be declining and may need further review. It has decreased from 913.00 Cr. (Mar 2025) to 861.00 Cr., marking a decrease of 52.00 Cr..
- For Expenses, as of Jun 2025, the value is 705.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 723.00 Cr. (Mar 2025) to 705.00 Cr., marking a decrease of 18.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 156.00 Cr.. The value appears to be declining and may need further review. It has decreased from 190.00 Cr. (Mar 2025) to 156.00 Cr., marking a decrease of 34.00 Cr..
- For OPM %, as of Jun 2025, the value is 18.00%. The value appears to be declining and may need further review. It has decreased from 21.00% (Mar 2025) to 18.00%, marking a decrease of 3.00%.
- For Other Income, as of Jun 2025, the value is 3.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Mar 2025) to 3.00 Cr., marking an increase of 2.00 Cr..
- For Interest, as of Jun 2025, the value is 2.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.00 Cr. (Mar 2025) to 2.00 Cr., marking a decrease of 2.00 Cr..
- For Depreciation, as of Jun 2025, the value is 11.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 13.00 Cr. (Mar 2025) to 11.00 Cr., marking a decrease of 2.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 145.00 Cr.. The value appears to be declining and may need further review. It has decreased from 173.00 Cr. (Mar 2025) to 145.00 Cr., marking a decrease of 28.00 Cr..
- For Tax %, as of Jun 2025, the value is 12.00%. The value appears to be increasing, which may not be favorable. It has increased from 1.00% (Mar 2025) to 12.00%, marking an increase of 11.00%.
- For Net Profit, as of Jun 2025, the value is 128.00 Cr.. The value appears to be declining and may need further review. It has decreased from 172.00 Cr. (Mar 2025) to 128.00 Cr., marking a decrease of 44.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 20.10. The value appears to be declining and may need further review. It has decreased from 27.01 (Mar 2025) to 20.10, marking a decrease of 6.91.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 5:49 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 404 | 431 | 397 | 431 | 513 | 843 | 1,767 | 1,867 | 2,009 | 2,255 | 2,328 | 2,709 | 2,729 |
| Expenses | 319 | 331 | 305 | 331 | 387 | 658 | 1,446 | 1,522 | 1,664 | 1,918 | 2,020 | 2,329 | 2,349 |
| Operating Profit | 85 | 100 | 91 | 99 | 125 | 185 | 321 | 344 | 345 | 337 | 308 | 380 | 380 |
| OPM % | 21% | 23% | 23% | 23% | 24% | 22% | 18% | 18% | 17% | 15% | 13% | 14% | 14% |
| Other Income | 19 | 28 | 32 | 32 | 35 | 28 | -33 | -123 | 10 | -5 | -0 | 19 | 18 |
| Interest | 0 | 0 | 0 | 1 | 2 | 30 | 140 | 84 | 26 | 16 | 24 | 12 | 11 |
| Depreciation | 0 | 8 | 7 | 7 | 9 | 13 | 26 | 25 | 24 | 25 | 24 | 28 | 34 |
| Profit before tax | 104 | 120 | 117 | 124 | 150 | 171 | 121 | 112 | 306 | 291 | 260 | 359 | 352 |
| Tax % | 5% | 7% | 10% | 10% | 9% | -0% | -17% | -6% | -1% | -7% | -3% | 3% | |
| Net Profit | 98 | 111 | 105 | 111 | 137 | 171 | 142 | 119 | 309 | 310 | 267 | 347 | 327 |
| EPS in Rs | 4.94 | 5.58 | 5.28 | 5.58 | 6.85 | 5.87 | 4.92 | 3.73 | 9.71 | 9.75 | 8.39 | 10.90 | 10.28 |
| Dividend Payout % | 24% | 22% | 25% | 23% | 23% | 17% | 20% | 27% | 10% | 10% | 12% | 11% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 13.27% | -5.41% | 5.71% | 23.42% | 24.82% | -16.96% | -16.20% | 159.66% | 0.32% | -13.87% | 29.96% |
| Change in YoY Net Profit Growth (%) | 0.00% | -18.67% | 11.12% | 17.71% | 1.39% | -41.78% | 0.76% | 175.86% | -159.34% | -14.19% | 43.83% |
Zydus Wellness Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 9% |
| 3 Years: | 10% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 13% |
| 3 Years: | 2% |
| TTM: | 6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 9% |
| 3 Years: | 14% |
| 1 Year: | 7% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 6% |
| 3 Years: | 6% |
| Last Year: | 6% |
Last Updated: September 4, 2025, 9:45 pm
Balance Sheet
Last Updated: June 16, 2025, 12:35 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 39 | 39 | 39 | 39 | 39 | 58 | 58 | 64 | 64 | 64 | 64 | 64 |
| Reserves | 286 | 367 | 439 | 518 | 652 | 3,329 | 3,403 | 4,504 | 4,780 | 5,059 | 5,294 | 5,608 |
| Borrowings | 0 | 0 | 0 | 25 | 25 | 1,569 | 1,519 | 550 | 387 | 297 | 329 | 188 |
| Other Liabilities | 99 | 102 | 89 | 100 | 112 | 503 | 610 | 548 | 461 | 413 | 462 | 582 |
| Total Liabilities | 425 | 508 | 568 | 682 | 829 | 5,459 | 5,590 | 5,666 | 5,692 | 5,833 | 6,148 | 6,442 |
| Fixed Assets | 95 | 84 | 82 | 103 | 104 | 4,567 | 4,674 | 4,667 | 4,710 | 4,732 | 4,708 | 5,125 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 10 | 4 | 4 | 12 | 13 | 10 | 15 |
| Investments | 5 | 0 | 94 | 30 | 148 | 46 | 110 | 0 | 27 | 70 | 78 | 36 |
| Other Assets | 324 | 423 | 391 | 550 | 577 | 835 | 802 | 995 | 943 | 1,018 | 1,354 | 1,266 |
| Total Assets | 425 | 508 | 568 | 682 | 829 | 5,459 | 5,590 | 5,666 | 5,692 | 5,833 | 6,148 | 6,442 |
Below is a detailed analysis of the balance sheet data for Zydus Wellness Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 64.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 64.00 Cr..
- For Reserves, as of Mar 2025, the value is 5,608.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,294.00 Cr. (Mar 2024) to 5,608.00 Cr., marking an increase of 314.00 Cr..
- For Borrowings, as of Mar 2025, the value is 188.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 329.00 Cr. (Mar 2024) to 188.00 Cr., marking a decrease of 141.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 582.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 462.00 Cr. (Mar 2024) to 582.00 Cr., marking an increase of 120.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 6,442.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6,148.00 Cr. (Mar 2024) to 6,442.00 Cr., marking an increase of 294.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 5,125.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,708.00 Cr. (Mar 2024) to 5,125.00 Cr., marking an increase of 417.00 Cr..
- For CWIP, as of Mar 2025, the value is 15.00 Cr.. The value appears strong and on an upward trend. It has increased from 10.00 Cr. (Mar 2024) to 15.00 Cr., marking an increase of 5.00 Cr..
- For Investments, as of Mar 2025, the value is 36.00 Cr.. The value appears to be declining and may need further review. It has decreased from 78.00 Cr. (Mar 2024) to 36.00 Cr., marking a decrease of 42.00 Cr..
- For Other Assets, as of Mar 2025, the value is 1,266.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,354.00 Cr. (Mar 2024) to 1,266.00 Cr., marking a decrease of 88.00 Cr..
- For Total Assets, as of Mar 2025, the value is 6,442.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,148.00 Cr. (Mar 2024) to 6,442.00 Cr., marking an increase of 294.00 Cr..
Notably, the Reserves (5,608.00 Cr.) exceed the Borrowings (188.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 85.00 | 100.00 | 91.00 | 74.00 | 100.00 | 184.00 | 320.00 | -206.00 | -42.00 | 40.00 | -21.00 | 192.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 2 | 1 | 3 | 3 | 6 | 42 | 24 | 18 | 26 | 34 | 44 | 49 |
| Inventory Days | 108 | 76 | 73 | 127 | 113 | 393 | 168 | 158 | 135 | 146 | 150 | 148 |
| Days Payable | 191 | 146 | 191 | 264 | 254 | 662 | 289 | 189 | 136 | 100 | 116 | 122 |
| Cash Conversion Cycle | -82 | -69 | -116 | -134 | -135 | -227 | -97 | -13 | 25 | 80 | 78 | 75 |
| Working Capital Days | -48 | -37 | -38 | -57 | -26 | -26 | -7 | -35 | -27 | 17 | 20 | 34 |
| ROCE % | 35% | 32% | 26% | 23% | 22% | 7% | 6% | 6% | 6% | 6% | 5% | 6% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 2,221,106 | 0.78 | 358.7 | 2,221,106 | 2025-04-22 15:57:01 | 0% |
| SBI Small Cap Fund | 1,034,243 | 0.67 | 167.03 | 1,034,243 | 2025-04-22 14:12:25 | 0% |
| ICICI Prudential Value Discovery Fund | 843,482 | 0.35 | 136.22 | 843,482 | 2025-04-22 15:57:01 | 0% |
| ICICI Prudential Multicap Fund | 243,627 | 0.37 | 39.34 | 243,627 | 2025-04-22 15:57:01 | 0% |
| Tata India Consumer Fund | 229,000 | 2.01 | 36.98 | 229,000 | 2025-04-22 15:57:01 | 0% |
| Aditya Birla Sun Life India GenNext Fund | 156,780 | 0.55 | 25.32 | 156,780 | 2025-04-22 15:57:01 | 0% |
| Tata Flexi Cap Fund | 140,000 | 0.85 | 22.61 | 140,000 | 2025-04-22 15:57:01 | 0% |
| ICICI Prudential Bharat Consumption Fund | 117,165 | 0.86 | 18.92 | 117,165 | 2025-04-22 15:57:01 | 0% |
| ICICI Prudential FMCG Fund - Dividend | 88,783 | 0.96 | 14.34 | 88,783 | 2025-04-22 15:57:01 | 0% |
| ICICI Prudential FMCG Fund - Growth | 88,783 | 0.96 | 14.34 | 88,783 | 2025-04-22 15:57:01 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 37.00 | 41.94 | 48.78 | 48.54 | 19.55 |
| Diluted EPS (Rs.) | 37.00 | 41.94 | 48.78 | 48.54 | 19.55 |
| Cash EPS (Rs.) | 59.01 | 45.71 | 52.71 | 52.25 | 22.61 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 891.76 | 842.37 | 805.07 | 761.28 | 717.87 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 891.76 | 842.37 | 805.07 | 761.28 | 717.87 |
| Revenue From Operations / Share (Rs.) | 425.93 | 366.01 | 354.36 | 315.75 | 293.36 |
| PBDIT / Share (Rs.) | 61.84 | 50.64 | 53.75 | 55.81 | 55.52 |
| PBIT / Share (Rs.) | 57.37 | 46.90 | 49.82 | 52.10 | 51.57 |
| PBT / Share (Rs.) | 56.41 | 40.90 | 45.71 | 48.09 | 17.63 |
| Net Profit / Share (Rs.) | 54.54 | 41.97 | 48.78 | 48.54 | 18.66 |
| NP After MI And SOA / Share (Rs.) | 54.54 | 41.97 | 48.78 | 48.54 | 18.66 |
| PBDIT Margin (%) | 14.51 | 13.83 | 15.16 | 17.67 | 18.92 |
| PBIT Margin (%) | 13.47 | 12.81 | 14.05 | 16.50 | 17.57 |
| PBT Margin (%) | 13.24 | 11.17 | 12.89 | 15.23 | 6.01 |
| Net Profit Margin (%) | 12.80 | 11.46 | 13.76 | 15.37 | 6.36 |
| NP After MI And SOA Margin (%) | 12.80 | 11.46 | 13.76 | 15.37 | 6.36 |
| Return on Networth / Equity (%) | 6.11 | 4.98 | 6.05 | 6.37 | 2.59 |
| Return on Capital Employeed (%) | 6.40 | 5.54 | 6.16 | 6.73 | 6.70 |
| Return On Assets (%) | 5.38 | 4.34 | 5.32 | 5.42 | 2.09 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.01 | 0.06 |
| Total Debt / Equity (X) | 0.03 | 0.06 | 0.05 | 0.07 | 0.12 |
| Asset Turnover Ratio (%) | 0.43 | 0.38 | 0.05 | 0.04 | 0.02 |
| Current Ratio (X) | 1.48 | 1.62 | 1.31 | 1.06 | 1.10 |
| Quick Ratio (X) | 0.78 | 1.02 | 0.65 | 0.58 | 0.62 |
| Inventory Turnover Ratio (X) | 2.40 | 2.24 | 0.89 | 0.78 | 0.54 |
| Dividend Payout Ratio (NP) (%) | 9.16 | 11.91 | 10.25 | 10.30 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 8.47 | 10.93 | 9.48 | 9.57 | 0.00 |
| Earning Retention Ratio (%) | 90.84 | 88.09 | 89.75 | 89.70 | 0.00 |
| Cash Earning Retention Ratio (%) | 91.53 | 89.07 | 90.52 | 90.43 | 0.00 |
| Interest Coverage Ratio (X) | 32.77 | 13.42 | 21.27 | 13.92 | 4.22 |
| Interest Coverage Ratio (Post Tax) (X) | 29.42 | 12.71 | 20.93 | 13.11 | 3.99 |
| Enterprise Value (Cr.) | 10742.16 | 9439.42 | 10116.33 | 9760.97 | 12849.96 |
| EV / Net Operating Revenue (X) | 3.97 | 4.05 | 4.49 | 4.86 | 6.88 |
| EV / EBITDA (X) | 27.31 | 29.31 | 29.58 | 27.48 | 36.37 |
| MarketCap / Net Operating Revenue (X) | 3.92 | 4.02 | 4.37 | 4.75 | 6.72 |
| Retention Ratios (%) | 90.83 | 88.08 | 89.74 | 89.69 | 0.00 |
| Price / BV (X) | 1.87 | 1.75 | 1.93 | 1.97 | 2.75 |
| Price / Net Operating Revenue (X) | 3.92 | 4.02 | 4.37 | 4.75 | 6.72 |
| EarningsYield | 0.03 | 0.02 | 0.03 | 0.03 | 0.01 |
After reviewing the key financial ratios for Zydus Wellness Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 37.00. This value is within the healthy range. It has decreased from 41.94 (Mar 24) to 37.00, marking a decrease of 4.94.
- For Diluted EPS (Rs.), as of Mar 25, the value is 37.00. This value is within the healthy range. It has decreased from 41.94 (Mar 24) to 37.00, marking a decrease of 4.94.
- For Cash EPS (Rs.), as of Mar 25, the value is 59.01. This value is within the healthy range. It has increased from 45.71 (Mar 24) to 59.01, marking an increase of 13.30.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 891.76. It has increased from 842.37 (Mar 24) to 891.76, marking an increase of 49.39.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 891.76. It has increased from 842.37 (Mar 24) to 891.76, marking an increase of 49.39.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 425.93. It has increased from 366.01 (Mar 24) to 425.93, marking an increase of 59.92.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 61.84. This value is within the healthy range. It has increased from 50.64 (Mar 24) to 61.84, marking an increase of 11.20.
- For PBIT / Share (Rs.), as of Mar 25, the value is 57.37. This value is within the healthy range. It has increased from 46.90 (Mar 24) to 57.37, marking an increase of 10.47.
- For PBT / Share (Rs.), as of Mar 25, the value is 56.41. This value is within the healthy range. It has increased from 40.90 (Mar 24) to 56.41, marking an increase of 15.51.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 54.54. This value is within the healthy range. It has increased from 41.97 (Mar 24) to 54.54, marking an increase of 12.57.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 54.54. This value is within the healthy range. It has increased from 41.97 (Mar 24) to 54.54, marking an increase of 12.57.
- For PBDIT Margin (%), as of Mar 25, the value is 14.51. This value is within the healthy range. It has increased from 13.83 (Mar 24) to 14.51, marking an increase of 0.68.
- For PBIT Margin (%), as of Mar 25, the value is 13.47. This value is within the healthy range. It has increased from 12.81 (Mar 24) to 13.47, marking an increase of 0.66.
- For PBT Margin (%), as of Mar 25, the value is 13.24. This value is within the healthy range. It has increased from 11.17 (Mar 24) to 13.24, marking an increase of 2.07.
- For Net Profit Margin (%), as of Mar 25, the value is 12.80. This value exceeds the healthy maximum of 10. It has increased from 11.46 (Mar 24) to 12.80, marking an increase of 1.34.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 12.80. This value is within the healthy range. It has increased from 11.46 (Mar 24) to 12.80, marking an increase of 1.34.
- For Return on Networth / Equity (%), as of Mar 25, the value is 6.11. This value is below the healthy minimum of 15. It has increased from 4.98 (Mar 24) to 6.11, marking an increase of 1.13.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.40. This value is below the healthy minimum of 10. It has increased from 5.54 (Mar 24) to 6.40, marking an increase of 0.86.
- For Return On Assets (%), as of Mar 25, the value is 5.38. This value is within the healthy range. It has increased from 4.34 (Mar 24) to 5.38, marking an increase of 1.04.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.03. This value is within the healthy range. It has decreased from 0.06 (Mar 24) to 0.03, marking a decrease of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.43. It has increased from 0.38 (Mar 24) to 0.43, marking an increase of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 1.48. This value is below the healthy minimum of 1.5. It has decreased from 1.62 (Mar 24) to 1.48, marking a decrease of 0.14.
- For Quick Ratio (X), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 1. It has decreased from 1.02 (Mar 24) to 0.78, marking a decrease of 0.24.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.40. This value is below the healthy minimum of 4. It has increased from 2.24 (Mar 24) to 2.40, marking an increase of 0.16.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 9.16. This value is below the healthy minimum of 20. It has decreased from 11.91 (Mar 24) to 9.16, marking a decrease of 2.75.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 8.47. This value is below the healthy minimum of 20. It has decreased from 10.93 (Mar 24) to 8.47, marking a decrease of 2.46.
- For Earning Retention Ratio (%), as of Mar 25, the value is 90.84. This value exceeds the healthy maximum of 70. It has increased from 88.09 (Mar 24) to 90.84, marking an increase of 2.75.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 91.53. This value exceeds the healthy maximum of 70. It has increased from 89.07 (Mar 24) to 91.53, marking an increase of 2.46.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 32.77. This value is within the healthy range. It has increased from 13.42 (Mar 24) to 32.77, marking an increase of 19.35.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 29.42. This value is within the healthy range. It has increased from 12.71 (Mar 24) to 29.42, marking an increase of 16.71.
- For Enterprise Value (Cr.), as of Mar 25, the value is 10,742.16. It has increased from 9,439.42 (Mar 24) to 10,742.16, marking an increase of 1,302.74.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.97. This value exceeds the healthy maximum of 3. It has decreased from 4.05 (Mar 24) to 3.97, marking a decrease of 0.08.
- For EV / EBITDA (X), as of Mar 25, the value is 27.31. This value exceeds the healthy maximum of 15. It has decreased from 29.31 (Mar 24) to 27.31, marking a decrease of 2.00.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.92. This value exceeds the healthy maximum of 3. It has decreased from 4.02 (Mar 24) to 3.92, marking a decrease of 0.10.
- For Retention Ratios (%), as of Mar 25, the value is 90.83. This value exceeds the healthy maximum of 70. It has increased from 88.08 (Mar 24) to 90.83, marking an increase of 2.75.
- For Price / BV (X), as of Mar 25, the value is 1.87. This value is within the healthy range. It has increased from 1.75 (Mar 24) to 1.87, marking an increase of 0.12.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.92. This value exceeds the healthy maximum of 3. It has decreased from 4.02 (Mar 24) to 3.92, marking a decrease of 0.10.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 24) to 0.03, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Zydus Wellness Ltd:
- Net Profit Margin: 12.8%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.4% (Industry Average ROCE: 16.32%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 6.11% (Industry Average ROE: 17.5%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 29.42
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.78
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 47.4 (Industry average Stock P/E: 120.8)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.03
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 12.8%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Food Processing - Bakery/Dairy/Fruits/Others | Zydus Corporate Park, Ahmedabad Gujarat 382481 | investor.grievance@zyduswellness.com http://www.zyduswellness.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Sharvil P Patel | Chairman |
| Mr. Tarun G Arora | WholeTime Director & CEO |
| Mr. Ganesh N Nayak | Non Executive Director |
| Mr. Kulin S Lalbhai | Independent Director |
| Mr. Akhil A Monappa | Independent Director |
| Mr. Srivishnu Raju Nandyala | Independent Director |
| Ms. Dharmishtaben N Raval | Independent Woman Director |
FAQ
What is the intrinsic value of Zydus Wellness Ltd?
Zydus Wellness Ltd's intrinsic value (as of 03 November 2025) is 407.35 which is 15.14% lower the current market price of 480.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 15,241 Cr. market cap, FY2025-2026 high/low of 531/299, reserves of ₹5,608 Cr, and liabilities of 6,442 Cr.
What is the Market Cap of Zydus Wellness Ltd?
The Market Cap of Zydus Wellness Ltd is 15,241 Cr..
What is the current Stock Price of Zydus Wellness Ltd as on 03 November 2025?
The current stock price of Zydus Wellness Ltd as on 03 November 2025 is 480.
What is the High / Low of Zydus Wellness Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Zydus Wellness Ltd stocks is 531/299.
What is the Stock P/E of Zydus Wellness Ltd?
The Stock P/E of Zydus Wellness Ltd is 47.4.
What is the Book Value of Zydus Wellness Ltd?
The Book Value of Zydus Wellness Ltd is 178.
What is the Dividend Yield of Zydus Wellness Ltd?
The Dividend Yield of Zydus Wellness Ltd is 0.25 %.
What is the ROCE of Zydus Wellness Ltd?
The ROCE of Zydus Wellness Ltd is 6.16 %.
What is the ROE of Zydus Wellness Ltd?
The ROE of Zydus Wellness Ltd is 6.02 %.
What is the Face Value of Zydus Wellness Ltd?
The Face Value of Zydus Wellness Ltd is 2.00.